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A B S T R A C T
To examine the outcomes of allogeneic stem cell transplantation (HSCT) in first complete remission (CR1) com-
pared with chemotherapy alone in a population-based setting, we identified a cohort of patients with acute
myeloid leukemia (AML) aged 15 to 70 years diagnosed between 2000 and 2014 in Denmark. Using the Danish
National Acute Leukemia Registry, we compared relapse risk, relapse-free survival (RFS), and overall survival
(OS) between patients with unfavorable cytogenetic features receiving postremission therapy with conven-
tional chemotherapy only versus those undergoing HSCT in CR1. To minimize immortal time bias, we performed
Cox proportional hazards regression, included date of allogeneic HSCT as a time-dependent covariate, and
stratified the results by age (<60 or ≥60 years) and cytogenetic risk group. Overall, 1031 patients achieved a
CR1. Of these, 196 patients (19%) underwent HSCT. HSCT was associated with a lower relapse rate (24% versus
49%) despite a similar median time to relapse (287 days versus 265 days). In all subgroups, the risk of relapse
was lower and both RFS and OS were superior in recipients of HSCT (OS, adjusted mortality ratios: all pa-
tients, .54 [95% confidence interval (CI), .42-.71]; patients age <60 years, .58 [95% CI, .42-.81]; patients age ≥60
years, .42 [95% CI, .26-.69]; patients with intermediate-risk cytogenetics, .63 [95% CI, .43-.87]; patients with
adverse-risk cytogenetics, .40 [95% CI, .24-.67]). In conclusion, in this population-based nationwide cohort
study, HSCT was associated with improved survival in both younger and older patients and in patients with
both intermediate and adverse cytogenetic risk.
© 2017 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-
HSCT) is a potentially curative treatment strategy for patients
with acute myeloid leukemia (AML) due to the antileuke-
mic effects of cytotoxic conditioning regimens and to the
immunologic graft-versus-leukemia effect mediated by donor
T cells [1,2]. Until recently, cytogenetic risk classification was
the most important criterion when selecting postremission
risk-adapted therapy [3], including HSCT in first complete re-
mission (CR1). Most patients achieving CR1 have intermediate-
risk cytogenetics, but to date, no truly randomized study has
been completed in these patients. Several studies have in-
vestigated the role of HSCT using genetic assignment
substituting for the lack of randomized trials on the basis of
the availability of a matched related donor (MRD); however,
these studies were not powered to examine survival within
cytogenetic subgroups. Three meta-analyses combining these
studies reported superior survival in the transplant groups
with intermediate cytogenetic risk only [4], with adverse
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cytogenetic risk only [5], and with both intermediate and
adverse cytogenetic risks [6]. In those studies, most pa-
tients underwent transplantation in the 1990s, and
extrapolation to current treatment practice is hampered by
the restricted use of matched unrelated donors (MUDs), the
younger age of subjects included in previous comparisons,
the limited number of reduced-intensity conditioning (RIC)
regimens, and higher transplantation-related morbidity [7].
More recently, authors have compared HSCT including both
RIC regimens and MUDs with chemotherapy only treat-
ment in selected populations of varying ages using different
methodological approaches [8-12],; however, none of these
studies has convincingly demonstrated an overall survival
benefit within cytogenetic subgroups after taking differ-
ences in characteristics between groups into consideration.
Although conventional chemotherapy has not changed
substantially over the last 2 decades, the field of allogeneic
transplantation has greatly expanded. The introduction of RIC
and nonmyeloablative (NMA) regimens and improved sup-
portive care has decreased transplantation-related morbidity,
which may translate into more significant clinical improve-
ment than previously reported in patients with AML. To
further investigate which patients are likely to benefit from
HSCT in CR1, we conducted a comparative effectiveness study
of the 2 postremission treatment options, HSCT and chemo-
therapy only, evaluating relapse risk, relapse-free survival
(RFS), and overall survival (OS) in Danish patients using the
Danish National Acute Leukemia Registry (DNLR).
METHODS
We conducted a population-based nationwide cohort study of 3486 pa-
tients with AML age ≥15 years registered in the DNLR between 2000 and
2014 [13]. The registry collects clinical data prospectively and covers 99.6%
of all patients with AML diagnosed in Denmark. Danish citizens (5.7 million
people) are entitled to free access to medical care provided by the public
tax-supported health care system, and no cancer treatment is provided
outside of these public centers [13,14]. During the study period, patients with
AML were treated with intensive therapy at 5 centers, and all HSCTs were
performed at 2 centers: Aarhus University Hospital and Rigshospitalet. Tissue
typing was recommended at the time of diagnosis for all patients without
contraindications for HSCT, and a donor search was initiated when cytoge-
netic results were available, at the discretion of the treating physician [15].
We included patients age ≤70 years who achieved CR after 1 or 2 cycles
of remission- induction chemotherapy. Patients with favorable cytoge-
netic risk features were excluded, because HSCT was not routinely
recommended for these patients (Figure 1A).
Clinical Data
We obtained baseline demographic data, laboratory test results, and in-
formation on chemotherapy and treatment response (morphological CR) [16]
from the DNLR. Cytogenetic results were grouped according to the Medical
Research Council’s 2010 revised criteria [17]. We obtained information on
non-AML-related comorbidities before the diagnosis of AML from the Danish
National Registry of Patients according to a modified version of the Charlson
Comorbidity Index [18,19]. Information on type of AML was grouped ac-
cording to World Health Organization criteria into secondary AML (s-AML;
including previous myelodysplastic syndrome or chronic myelomonocytic
leukemia, myeloproliferative neoplasm, or other), and therapy-related AML
(t-AML) [20]. As a surrogate for complications during remission-induction
therapy, we calculated the cumulative length of hospital stay between the
date of AML diagnosis (day 0) and day 100.
Therapy Including HSCT
Intensive chemotherapy was defined as selection for 2 courses of
remission-induction therapy including cytarabine (≥100-400 mg/m2/day) [21]
in combination with an anthracycline or anthracycline-like compound.
Postremission therapy consisted of 1 or 2 courses of consolidation therapy
(eg,amsacrine/cytarabine/etoposide, mitoxantrone/cytarabine high-dose
cytarabine).
A national board generates consensus recommendations for allo-HSCT
in AML in Denmark [15]. The recommendation is to perform HSCT in CR1
following 1 or 2 courses of consolidation therapy in patients with an
adverse-risk karyotype and those with a normal karyotype and the pres-
ence of an FLT3-ITD+/NPM1- mutation (since 2010). In intermediate-risk
patients before 2010 and in patients without an FLT3-ITD+/NPM1- muta-
tion after 2010, HSCT was done at the discretion of the treating physician
or according to clinical trials. The intensity of the conditioning regimen was
based on current guidelines (age <50 years, myeloablative conditioning [MAC];
age 50-70 years, NMA), but the final decision was left to the attending
physician.
Information on transplantation-related factors was obtained from local
transplantation registries and included disease state at time of transplan-
tation (CR1, CR2, not in CR), conditioning regimen (MAC/NMA), graft type
(peripheral blood stem cells or bone marrow), and donor source (MRD, MUD,
or umbilical cord blood). Detailed descriptions of the use of immunosup-
pressive therapy are available elsewhere [22].
Outcome
We obtained information on all-cause mortality and emigration through
linkage to the Civil Registration System [23]. The date of confirmed relapse
and detailed information on cause of death were obtained from the DNLR
and local transplantation registries. Relapse was defined as measurement
of >5% blasts in the bone marrow or the development of extramedullary
myeloid lesions in a patient with previously documented CR. If the cause
of death was registered as “progressive disease” or “relapse” and a date of
relapse was missing, medical records were reviewed. RFS was defined as the
time from the date of CR1 to the date of first relapse or death in CR1.
Statistical Analyses
Descriptive results
We stratified descriptive data by group (HSCT in CR1 or chemotherapy-
only) and computed the median time to HSCT from both diagnosis and from
CR1 overall, by donor type, and by conditioning regimen. Patients were fol-
lowed from CR1 until death, emigration, or end of follow-up (February 18,
2016).
Comparative effectiveness of HSCT versus intensive therapy only; relapse risk,
RFS, and OS using time of HSCT as a time-dependent exposure. We com-
puted crude and adjusted mortality ratios comparing patients who underwent
HSCT with those who received chemotherapy only using a Cox proportion-
al hazards regression model, considering time of allo-HSCT as a
time-dependent exposure. In essence, this approach assigns person-time
(follow-up) for individuals before HSCT to the chemotherapy-only group.
We estimated the RFS (hazard ratio [HR]) as a composite endpoint (relapse
or death in CR1). Log-log plots were used to graphically verify that the pro-
portional hazards assumption was not violated. We computed the risk of
relapse using a Cox proportional hazards regression model, accounting for
competing risk by censoring at death in CR1.
We present crude results and confounder-adjusted results (adjusted for
sex, age, propensity score [PS], s-AML/t-AML, WBC, cytogenetic risk group,
cumulative length of hospital stay within the first 100 days, and year of trans-
plantation). All results were further presented overall and stratified by age
(<60 or ≥60 years) and cytogenetic risk group (intermediate or adverse risk).
Sensitivity analysis: relapse risk, cumulative incidence of relapse, RFS, and
OS using a landmark approach. We conducted landmark analyses to graph-
ically compare relapse risk and survival and to assess the robustness of the
time-dependent covariate approach. We started follow-up at days 200
(primary) and 365 (secondary) from diagnosis, to evaluate whether choice
of landmark had an impact on interpretation of the landmark analyses. Pa-
tients in whom death, end of follow-up, or relapse occurred before the
landmark were excluded. Patients undergoing HSCT before the landmark were
categorized in the HSCT group, whereas those undergoing HSCT after the
landmark were included in the chemotherapy-only group (Figure 1). This
approach avoids immortal-time bias by synchronizing the start of follow-
up for both treatment groups [24]. We computed the cumulative risk of
relapse (using Fine and Gray methods) and created Kaplan-Meier plots overall
and by subgroups. Subgroups were compared using the log-rank test.
To minimize confounding when comparing the effectiveness of HSCT with
intensive chemotherapy only, we computed a PS for each individual, which
predicted the probability of undergoing HSCT in CR1 conditional on the in-
dividual’s observed baseline factors using multivariable logistic regression
[25-27].
The PS model included factors associated with referral to HSCT in CR1
and outcome, or to outcome alone, including age (<30, 30-39, 40-49, 50-
59, 60-70 years), sex, WBC at diagnosis, World Health Organization
performance status, cytogenetic risk group (imputing missing as the inter-
mediate risk group), type of AML, comorbidity at time of AML diagnosis, and
cumulative length of hospital stay over days 0 to 100.
We balanced these factors across the treatment groups using standard-
ized mortality ratio (SMR) weighting [28], and evaluated the covariate balance
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using standardized absolute mean difference, with a value <.1 considered
to indicate adequate balance [29,30].
We then calculated crude and adjusted (via SMR weighting) HRs for OS,
RFS, and relapse risk, comparing patients who underwent HSCT and those
receiving chemotherapy only using a Cox proportional hazards regression
model.
The study protocol was approved by the Danish Data Protection Agency
(j.nr. 2012-41-0878) and the National Board of Health (j.nr.3-3013-158). All
analyses were performed using the Stata 13.0 package (StataCorp, College
Station, TX).
RESULTS
Patient and Treatment Characteristics
The final study population comprised 1031 patients. Se-
lection of the study population is shown in Figure 1. A total
of 196 patients (19.0%) underwent transplantation in CR1.The
proportion of patients who underwent transplantation in-
creased during the study period (2000-2004, 10.9%; 2005-
2009, 20.0%; 2010-2014, 26.6%). The median patient age was
56 years (range, 16-70 years), and 52.8% were men. The char-
acteristics of all patients and of the matched cohort by
treatment status are presented in Table 1. The HSCT recipi-
ents were generally younger, had less comorbidity, and had
better performance status at diagnosis. However, more HSCT
recipients had s-AML and adverse cytogenetics or abnor-
mal karyotype.
The total follow-up time in the cohort was 4202 person-
years, with a median duration of 2.2 years. During this time,
654 patients (63.4%) died (571 in the chemotherapy-only
group and 83 in the HSCT group). The time from diagnosis
to CR1 did not differ between the HSCT and chemotherapy-
only groups (39 days; interquartile range [IQR], 33-67 days
versus 37 days; IQR, 32-51 days). All chemotherapy-only pa-
tients received at least 1 cycle of induction chemotherapy,
89% received 2 cycles, 70% received 1 consolidation regimen,
and 40% received 2 or more consolidation regimens. The cor-
responding proportions in the HSCT group were 100%, 91%,
74%, and 24%. The remission-induction regimens used dif-
fered between the 2 groups. HSCT recipients more often
received remission-induction therapy with daunorubicin and
cytarabine with or without etoposide (DA/ADE; 71%),
idarubicin and cytarabine (16%), or FLAG-based regimens (6%).
In contrast, the chemotherapy-only cohort received DA/
ADE (42%), idarubicin and cytarabine (30%), and mitoxantrone-
based regimens (18%).
Conditioning Regimens in HSCT Recipients
Transplantation-related information for the 196 pa-
tients who underwent transplantation in CR1 is provided in
Table 1. The median time from diagnosis to HSCT was 182
days (IQR, 152-216 days), and the median time from CR1 to
HSCT was 128 days (IQR, 97-169 days), including 143 days
(IQR, 120-203 days) in MUD recipients, 112 days (IQR, 79-
134 days) in MRD recipients, 119 days (IQR, 76-162 days) in
patients receiving MAC, and 133 days (IQR, 106-170 days) in
those receiving NMA conditioning. In patients age <60 years,
48.5% received a MAC regimen, and all patients age ≥60 years
received NMA conditioning. A graft from a related donor was
Figure 1. Study cohort inclusion and exclusion diagram. The flow chart shows the selection process for the main analysis using time-dependent covariates
and for the secondary landmark analyses using the day 200 and day 365 landmarks.
LM, landmark.
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more common in younger patients than in older patients (56%
versus 25%). In total, 97% of the patients received a 10/10 or
9/10 HLA-matched graft. MAC regimens consisted of cyclo-
phosphamide 120 mg/kg and total body irradiation (TBI)
12.5 Gy (in 90% of the patients), busulfan 12.8 mg/kg and
cyclophosphamide 120 mg/kg (in 9%), or fludarabine 150 mg/
m2 and treosulfane 42 g/m2 (in 1%). NMA conditioning
regimens included fludarabine 90 mg/m2 and TBI 2 Gy (in
92%); fludarabine 160 mg/m2, cyclophosphamide 50 mg/kg,
and TBI 2 Gy (4.8%); and fludarabine 90 mg/m2 and TBI 4 Gy
(in 2.4%) or TBI 3 Gy (in 1%). No survival difference was seen
between MAC and NMA conditioning groups (age <60 years;
P = .20) or between MUD and MRD groups (P = .70, log-rank
test).
Risk of Relapse and RFS Overall and by Age and
Cytogenetic Risk Group
Relapse occurred in 47 patients (24.0%) in the HSCT group,
compared with 411 patients (49.2%) in the chemotherapy-
only group, but these was no between-group difference in the
median time from CR1 to relapse (265 days [IQR, 157-466
days] in the chemotherapy-only group versus 287 days [IQR,
216-591 days] in the HSCT group). When censoring pa-
tients at death in CR, the crude and adjusted risks of relapse
were higher in the chemotherapy-only group (adjusted HR
[aHR], .37; 95% CI, .26-.53). This effect was comparable across
age and cytogenetic risk groups (Table 2).
The median RFS was 293 days (IQR, 142-910 days) in the
chemotherapy-only group and 1068 days (IQR, 397-2698 days)
in the HSCT group. The crude and adjusted results of the re-
gression analysis for RFS are shown in Table 2. Both crude and
adjusted estimates of RFS overall and within age and cyto-
genetic subgroups were superior in the HSCT cohort compared
with the chemotherapy-only cohort. The effect of HSCT on
RFS tended to be greater in older patients compared with
younger patients (aHR, .38 [95% CI, .23-.62] versus .52 [95%
CI, .38-.71]), whereas a similar effect was seen in adverse-
risk and intermediate-risk patients (aHR, .44 [95% CI, .26-
.75] versus .52 [95% CI, .38-.71]).
Adjusted survival overall and within subgroups
The median OS was 476 days (IQR, 167-1589 days) in the
chemotherapy-only group and 1173 days (IQR, 474-2859 days)
in the HSCT group. The results of the overall crude and ad-
justed survival analyses are shown in Figure 2. Overall and
within all subgroups, the HSCT group had superior survival
(aHR: overall, .54 [95% CI, .42-.71]; younger patients, .58 [95%
CI, .42-.81]; older patients, .42 [95% CI, = .26-.69]; intermediate-
risk patients, .63 [95% CI, .43-.87]; adverse-risk patients, .40
[95% CI, .24-.67]) compared with the chemotherapy-only
group.
Within s-AML categories, s-AML patients with previous
myelodysplastic syndrome or chronic myelomonocytic leu-
kemia had superior outcomes after allo-HSCT compared with
after chemotherapy only (aHR, .35; 95% CI, .14-.92). In con-
trast, allo-HSCT recipients with t-AML or s-AML and previous
myeloproliferative neoplasm had outcomes comparable to the
chemotherapy-only group (aHR, .80 [95% CI, .10-3.88] versus
1.09 [95% CI, .30-4.02]).
Relapse Risk, RFS, and OS Using a Landmark Approach
To allow for a visual comparison between the HSCT and
chemotherapy-only groups and consideration of competing
risks, we reanalyzed the data using a landmark approach,
starting follow-up at day 200 (n = 794, including 114 allo-
HSCT recipients in CR1) and at day 365 (n = 596, including
146 allo-HSCT recipients in CR1). Confounders were well bal-
anced using PS weighting (Supplementary Figure S1).
Table 1
Patient and Transplantation-Related Characteristics According to Treat-
ment in All Patients and by Age
Characteristic Entire Cohort (n = 1031)
HSCT in CR1
(n = 196; 19.0%)
Chemotherapy-Only
(n = 835; 81.0%)
Patient characteristics
Male sex, n (%) 107 (54.6) 437 (52.3)
Age, yr, median (range) 53 (17-70) 57 (15-70)
Comorbidities, n* (%)
0 151 (85.3) 587 (75.1)
1 21 (11.9) 145 (18.5)
≥2* 5 (2.8) 50 (6.4)
WHO performance status,
n (%)
0 90 (45.9) 314 (37.6)
1 83 (42.4) 393 (47.1)
≥2 23 (11.7) 128 (15.3)
t-AML, n (%) 6 (3.1) 50 (6.0)
s-AML, n (%) 35 (17.9) 85 (10.2)
Disease characteristics
Time to treatment
initiation, d, median (IQR)
4 (1-7) 3 (1-7)
Cumulative length of
hospital stay (days 1-100),
n (%)
0-29 d 45 (25.4) 184 (24.0)
30-60 d 92 (52.0) 403 (52.5)
≥60 d 40 (22.6) 181 (23.6)
Blast count in marrow, %,
median (IQR)
52 (32-80) 56 (33-80)
Blast count blood, %,
median (IQR)
17 (1-56) 25 (5-61)
WBC, × 109/L, median (IQR) 6 (2-36) 10 (2-31)
Platelet count, × 109/L,
median (IQR)
71 (37-119) 58 (31-107)
Cytogenetics risk group,
MRC 2010, n, (%)
Intermediate risk 116 (73.0) 619 (83.8)
Adverse risk 43 (27.0) 120 (16.3)
Missing 22 (11.2) 96 (11.4)
Cytogenetics, karyotype,
n (%)
Normal 93 (52.8) 449 (60.6)
Abnormal 83 (47.2) 292 (39.4)
Transplantation-related
characteristics
Conditioning regimen,
n (%)
MAC 70 (35.7)
NMA 126 (64.3)
Donor source, n (%)
MRD 91 (46.4)
MUD 99 (50.1)
Umbilical cord blood 6 (3.1)
HLA match, n (%)
10/10 or 10/9
HLA-identical match
183 (93.4)
1 antigen mismatch 7 (3.6)
Umbilical cord blood 6 (3.1)
Time from diagnosis to
HSCT in CR1, d,
median (range)
182 (152-216)
Time from CR to
transplantation in CR1, d,
median (range)
128 (98-168)
WHO indicates World Health Organization; MRC, Medical Research Council.
* According to the modified Charlson Comorbidity Index, which in-
cludes non-leukemia-related comorbidity.
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The cumulative incidences of relapse overall and within
subgroups for the day 365 landmark cohort are shown in
Figure 3. At 1 year from CR1, the risk of relapse remained lower
in patients undergoing transplantation before day 365. Crude
survival was superior overall and within subgroups in HSCT
recipients undergoing transplantation within 1 year from di-
agnosis (Figure 4). The cumulative incidence of relapse
and crude OS for the day 200 landmark are shown in
Supplementary Figures S2 and S3.
Using day 180 (or median time to HSCT) as a landmark
resulted in estimates comparable to those of the day 200 land-
mark analyses (results not shown).
Our use of the landmark approach did not change the in-
terpretation of the primary results using the time-dependent
covariate analysis with follow-up starting at CR1. However,
owing to smaller cohorts, shorter follow-up time, the start
of follow-up several months after an eventual HSCT was per-
formed, and the inclusion of true HSCTs in the unexposed
group, especially in the day 200 landmark analysis, the
estimates differed among the 3 approaches and were less
precise in the landmark analyses, especially for the small sub-
group of adverse-risk patients who were alive and relapse-
free after the landmark. Relapse risk, RFS, OS, and crude and
SMR-weighted results for both landmarks are presented in
Supplementary Tables S2–S4.
DISCUSSION
In this large and contemporary population-based study
of patients with AML, we found that postremission therapy
with HSCT in CR1 was superior to consolidation chemother-
apy in otherwise comparable patients. HSCT was associated
with improved relapse rate, RFS, and OS both overall and
within subgroups of patients stratified by age or cytoge-
netic risk group. Interestingly, time to relapse was not different
in the 2 groups.
To our knowledge, this is the first population-based study
directly comparing patients with AML treated with conven-
tional chemotherapy only with those receiving additional
Table 2
Crude HRs and aHRs Comparing HSCT versus Chemotherapy-Only and the Risk of Relapse and RFS Analyses Considering Transplantation as a Time-
Dependent Covariate
Relapse Risk* RFS†
Crude HR (95% CI) aHR‡ (95% CI) Crude HR (95% CI) aHR‡ (95% CI)
Overall
HSCT in CR1 .45 (.33-.61) .37 (.26-.53) .54 (.43-.68) .48 (.37-.62)
Chemotherapy-only 1 1 1 1
Stratified by age
<60 yr
HSCT in CR1 .45 (.31-.65) .39 (.25-.59) .58 (.44-.77) .52 (.38-.71)
Chemotherapy-only 1 1 1 1
≥60 yr
HSCT in CR1 .45 (.27-.78) .34 (.18-.65) .49 (.33-.74) .38 (.23-.62)
Chemotherapy-only 1 1 1 1
Stratified by cytogenetics
Intermediate risk
HSCT in CR1 .35 (.23-.54) .35 (.23-.55) .50 (.38-.68) .52 (.38-.70)
Chemotherapy-only 1 1 1 1
Adverse risk
HSCT in CR1 .64 (.36-1.11) .46 (.24-.87) .52 (.33-.82) .44 (.26-.75)
Chemotherapy-only 1 1 1 1
* Patients are censored at death in CR.
† Relapse and death in CR served as a composite endpoint.
‡ Adjusted for age, sex, WHO performance status, type of AML (de novo, s-AML, or t-AML), WBC, cytogenetic risk group, comorbidity, cumulative length of
hospital stay in days 0-100, and year of diagnosis.
Figure 2. Forest plot of the crude HRs and aHRs comparing HSCT versus chemotherapy only and OS after CR by subgroup, considering transplantation as a
time-dependent covariate.
*Adjusted for age, sex, World Health Organization performance status, type of AML (de novo, s-AML, or t-AML), WBC, cytogenetic risk group, comorbidities,
cumulative length of hospital stay between day 0 and day 100, and year of diagnosis.
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consolidation with HSCT within cytogenetic risk groups. The
population-based design with a large number of patients and
long follow-up allowed for sufficient statistical power to eval-
uate the effect of HSCT within age and cytogenetic risk groups
using advanced statistical methods to control for measured
confounding. The accuracy and completeness of our data have
been confirmed as high through various validation pro-
cesses [31,32], and the transplantation-related data were
validated using medical records, thereby minimizing
misclassification bias. In addition, complete follow-up data
were available. Finally, the inclusion of patients treated within
the last 15 years ensured generalizability to current treat-
ment strategies and outcomes.
We found a survival benefit of HSCT as a postremission
treatment strategy across age and cytogenetic risk groups. In
general, previous studies of mainly younger patients failed
to show an overall survival benefit from HSCT, with incon-
sistent findings regarding the effect within cytogenetic risk
groups [4-6,10,32-34]. These differences are likely explained
by improved supportive care and transplantation effective-
ness over time, heterogeneity of treatment regimens and
patient characteristics, as well as the use of donor versus no-
donor comparisons in earlier studies. The donor versus no-
donor approach is likely to underestimate the antileukemic
effect of HSCT, given that only 50% to 75% of patients actu-
ally receive the assigned treatment.
Figure 3. Crude cumulative incidence of relapse, using death as a competing risk and day 365 as a landmark, overall (A), in patients age <60 years (B), in
patients age ≥60 years (C), in patients with intermediate-risk cytogenetics (D), and in patients with adverse-risk cytogenetics (E).
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In the light of the increasing use of MUDs, other meth-
odological approaches are now used to compare survival
between patients receiving MAC or NMA HSCT to those re-
ceiving consolidation only [8,9,12,35,36]. However, the
conclusions from these reports are limited by various
methodological limitations. Juliusson et al. [35] reported
that a higher HSCT rate in patients age <60 years in a
population-based setting was associated with overall supe-
rior long-term survival, and Kurosawa et al. [8] reported
superior survival in patients with intermediate and adverse
cytogenetic risk undergoing NMA-conditioned HSCT com-
pared with those receiving chemotherapy only. However, in
both of those studies, only crude results were reported, and
thus confounding by indication could be present. In another
Figure 4. Crude survival in patients with AML by treatment for the day 365 landmark analysis. Kaplan-Meier plots show crude survival for the study popu-
lation overall (A), in patients age <60 years, (B), in patients age ≥60 years (C), in patients with intermediate-risk cytogenetics (D), and in patients with adverse-
risk cytogenetics (E). Superior survival is seen overall and within the subgroups.
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study, postremission use of NMA HSCT was associated with
a survival benefit in older patients, but these results were not
controlled for clinical confounders such as comorbidities, and
the series included a large proportion of chemotherapy-
only patients who did not receive any consolidation
chemotherapy, which might have biased results toward a su-
perior outcome in the HSCT recipients [36]. Recently, Russell
et al. [12] reported superior survival overall and within in-
termediate and adverse cytogenetic risk group in younger
HSCT patients compared to chemotherapy-only, however, this
analysis was restricted only to patients receiving an al-
lograft from a MRD.
Other studies have shown that RIC/NMA-based transplan-
tation conditioning regimens are well tolerated in older patients,
and that the effect is not age-dependent [37,38]. In our study,
patients age ≥60 years achieved a similar reduction in RFS as
younger patients, despite the use of MAC regimens in ~50% of
patients age <60 years. Our results confirm that the use of NMA
conditioning expands the application of HSCT in patients with
AML of advanced age or with comorbidities, who are not oth-
erwise candidates for MAC HSCT [39].
We also found the relative reduction in relapse risk and
RFS within the intermediate risk group to be comparable to
that seen in adverse risk patients.
The European Leukemia Networking party has suggested
that HSCT should be performed in patients when the pro-
cedure is expected to improve RFS by 10% or more, based on
pretransplantation assessments of relapse risk and NRM [39].
In our study, we observed a >10% difference not only in RFS,
but also in OS, between HSCT and chemotherapy-only
patients for all subgroups. Nonetheless, relapse remains a
major problem after HSCT, and therapeutic strategies for post-
HSCT relapse of AML are much needed. In the present study,
one-fourth of the HSCT recipients experienced relapse, in
agreement with results from large clinical trials reporting
relapse rates ranging from 24% to 37% [40]. Novel targeting
agents or adjuvant post-transplantation treatments, such as
low-dose demethylating agents (eg, azacytidine) have been
suggested to increase the graft-versus-leukemia effect. FLT3
inhibitor therapy post-transplantation is currently undergo-
ing prospective evaluation in clinical trials, with the aim of
reducing the risk of relapse [41-43].
The patients in the chemotherapy-only group received
more cycles of chemotherapy than those in the HSCT group,
and although the remission-induction regimens differed
slightly between the 2 groups, DA/ADE, FLAG, and idarubicin-
based induction chemotherapy have shown similar outcomes
[44-46]. It was not possible to include different transplanta-
tion approaches, such as donor source or the level of HLA
matching, in the analysis; however, given that 94% of pa-
tients undergoing transplantation in CR1 had a 9/10 or
10/10 HLA match, and that there was no survival difference
between MUD and MRD graft recipients, these factors
were less likely to have affected the results. This is sup-
ported by previous studies showing comparable survival in
HSCT recipients with MUD and MRD grafts [11,46] as well
as similar relapse risk and survival in HSCT recipients
conditioned with NMA and those conditioned with MAC
[22,47].
In recent years, molecular data have refined the prognos-
tication of the large intermediate-risk group, adding the
recommendation for HSCT in patients with a normal karyo-
type with an FLT3-ITD+/NPM1- mutation in 2010. We did not
have molecular information, including minimal residual
disease, for all patients, and thus we could not take this into
consideration in our analyses and address whether—based
on molecular alterations—chemotherapy only would have
been at least equal to HSCT within a subgroup of intermediate-
risk patients.
The time from CR1 to HSCT in our series did not differ from
that reported by Mohty et al. [10] and Farag et al. [48], but
was shorter than reported in another recent study (172 days
[11] versus 128 days), owing primarily to a shorter time to
HSCT in recipients of MUD grafts in our study. This indi-
cates early tissue typing and an efficient search for unrelated
donors through national and international registries. Al-
though, it is recommended that HSCT should be performed
as early as possible after induction chemotherapy to prevent
unnecessary treatment-related morbidity, which could pre-
clude patients from proceeding to HSCT, the observed time
to transplantation shows that consolidation chemotherapy
can be avoided in only a very few patients. Improvements in
supportive care after transplantation and the use of new con-
ditioning regimens have led to improved outcomes over time
[7].
Our study has some limitations. The patients were not
randomized to allo-HSCT, which introduced confounding
by indication, because some chemotherapy-only patients
might have been scheduled for allo-HSCT but could have
experienced relapse or death before undergoing transplan-
tation. To avoid immortal-time bias, we primarily used time
of transplantation as a time-dependent covariate, in which
allo-HSCT recipients contribute follow-up time to the
chemotherapy-only group until the day of transplantation
in CR1. Second, we used a landmark approach, in which
immortal-time bias is avoided by synchronizing the start of
follow-up for all individuals in the 2 treatment groups. The
landmark approach restricts the analytic cohort by exclud-
ing patients who experience early outcomes, who do not
have the opportunity to undergo allo-HSCT (and thus are
not truly exchangeable with those who actually undergo
allo-HSCT). Inclusion of these individuals would artificially
exaggerate the beneficial effects of allo-HSCT compared with
the chemotherapy-only approach. Moreover, the use of an
active comparator (ie, chemotherapy-only) and PS weight-
ing helped reduce confounding by measured indication and
frailty [24]. However, because the landmark approach pre-
vented us from comparing outcomes before day 200/day
365 and this approach would (depending on choice of land-
mark) misclassify a proportion of allo-HSCT recipients as
chemotherapy-only patients, we used time-dependent
covariate analyses as our main analytic approach. Nonethe-
less, we found that the 2 different approaches generated
comparable results for RFS and OS in all subgroups, strength-
ening our study conclusions. We lacked information on
reasons why chemotherapy-only patients did not receive
HSCT; however, the wide extent of clinical information used
in this study including, comorbidities, performance status,
and time spent in the hospital, in combination with the use
of PS weighting, allowed us to compare the 2 treatment
approaches. Even still, however, residual confounding might
have affected the results toward a superior survival in HSCT
recipients.
In conclusion, our results indicate that the antileukemic
effect of HSCT can improve RFS and OS in a large fraction of
both younger and older patients with intermediate and
adverse cytogenetic risk features. The field of HSCT is con-
stantly developing, and a continued effort should be made
to conduct clinical prospective trials comparing HSCT and
nonallogeneic treatments.
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